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INTRODUCTION
 Mother’s body faces a great cardiovascular and 
metabolic challenge during pregnancy. One of the 
most prevalent events is increasing blood pressure. 
Hypertensive disorders which affect 10% of all 
pregnancies and contribute greatly to maternal 
and perinatal mortality throughout the world, 
includes a wide spectrum of conditions, including 
pre-eclampsia and eclampsia, pre-eclampsia 
superimposed on chronic hypertension, chronic 
hypertension, and gestational hypertension.1
 Preeclampsia can be devastating and life-
threatening for both mother and fetus. Overall, 
10% to 15% of maternal deaths are associated 
with preeclampsia and eclampsia. In developing 
countries, it is much higher in some parts of Africa 
and Asia compared to Western nations.2,3
1. Bakhshandeh Nosrat S, MD,
 Gynecologist, Assistant Professor,
2. Azarhoosh R, MD,
 Pathologist, Associate Professor,
3. Borghei A, MD,
 Specialist in Social Medicine, Assistant Professor,
 Golestan University of Medical Sciences, Iran.
4. Sedaghati M, MD,
5. Besharat S, MD,
6. Ghaemi E, PhD,
       Associate Professor, 
1,6: Golestan University of Medical Sciences, 
 Infectious Disease Research Center, Iran.
2,5: Golestan University of Medical Sciences, Golestan Research 
 Center of Gastroenterology and Hepatology, Iran.
 Correspondence:
 Bakhshandeh Nosrat S, MD,
 3rd Floor, Shahid Nabavi Polyclinic, 4th Azar, 5-Azar St,
 Gorgan City, Golestan Province, Iran.
 E-mail: sepidehbn@yahoo.com
  * Received for Publication: January 5, 2011
  * Revision Received: October 1, 2011
  * Revision Accepted: October 5, 2011
Original Article
Serum level of Lactate dehydrogenase, Homocystein, 
Hemoglobin and platelet in preeclampsia
Bakhshandeh Nosrat S1, Azarhoosh R2, Borghei A3,
Sedaghati M4, Besharat S5, Ghaemi E6
ABSTRACT
Objectives: Pre-eclampsia affects approximately 5–8% of pregnant women. The aim of this study 
was to compare the serum level of Lactate dehydrogenase (LDH), Homocystein, Hemoglubin 
and platelet in pregnant women diagnosed as pre-eclampsia and a normal group in Gorgan city, 
Northeastern Iran from 2007-2008.
Methodology: In this case control study, 50 cases of pre-eclampsia were compared with the 
control group women hospitalized in Dezyani hospital. Pre-eclampsia criteria were: Blood 
pressure more than or equal to 140/ 90 mm hg and Proteinuria greater or equal to 300 mg/ 24 
hours urine sample in the third trimester. Hemoglobin, platelet, LDH and hemocystein were 
measured. Data were analyzed by the mean of SPSS-14 program & Chi-2 or t-student were used.
Results: The difference of BMI and family incomes was significant between two groups 
(P-value<0.01). LDH level was not statistically different between healthy and pre-eclamptic 
individuals. Six cases (12%) in controls and 9 cases (18%) in pre-eclamptic group had 
thrombocytopenia (P-value>0.01). Hemocystein level was more than normal range in five 
patients with pre-eclampsia (P-value<0.001).
Conclusions: In this study, hemocystein level was significantly higher in pre-eclampsia patients 
but LDH, hemoglobin and platelet level had no significant difference.
KEY WORDS: Hemocystein, Lactate Dehydrogenase (LDH), Hemoglobin, Platelet, Preeclampsia, 
Eclampsia, Proteinuria.
Pak J Med Sci   October - December 2011   Vol. 27   No. 5  1014-1017
How to cite this article:
Bakhshandeh Nosrat S, Azarhoosh R, Borghei A, Sedaghati M, Besharat S, Ghaemi E. Serum level 
of Lactate dehydrogenase, Homocystein, Hemoglobin and platelet in preeclampsia. Pak J Med 
Sci 2011;27(5):1014-1017
   Pak J Med Sci   2011   Vol. 27   No. 5      www.pjms.com.pk   1015
Some serological factors in preeclampsia
 Pre-eclampsia affects approximately 5–8% of 
pregnant women. Maternal death rates from pre-
eclampsia have been significantly reduced by careful 
patient management in the developed world, but 
not in developing countries, which account for 99% 
of total annual global maternal deaths.4
 This disease is a especial situation that occurs only 
in human pregnancy and presents with hypertension 
and proteinuria after 20 weeks of pregnancy. The 
main cause of preeclampsia is unknown, however, 
abnormal placentation is thought to be responsible 
to an inflammatory-type response with endothelial 
dysfunction. Different etiologies have been known 
in preeclampsia include immunologic factors, 
genetic, nutrition, race, increased insulin resistance, 
oxidative stress and imbalance of prostaglandins 
oxidative stress by free radicals. Different markers 
are determined for the early diagnosis of pre-
eclampsia like kidney and liver markers, vascular 
function markers (like hemocystein clotting system, 
fibrinolytic platelet,…), etc.5
 Early onset disease would be result of a poor 
early placentation and late onset pre-eclampsia is 
originated from exaggerated systemic inflammatory 
response such as predisposing cardiovascular 
or metabolic risks for endothelial dysfunction. 
Prevention and prediction are still not possible due 
to the unknown origin, and preventing maternal 
morbidity (eg, eclampsia) and mortality could be 
done via clinical management.3 
 The most common hematologic disorder in pre-
eclampsia is thrombocytopenia (platelet count < 
100,000/mm3) with unknown mechanism. Some 
authors have concluded that lactic dehydrogenase 
(LDH) is a useful biochemical marker that reflects 
the severity and occurrence of complications in pre-
eclampsia.5,6 LDH and platelet  count is  found to 
be useful in predicting the progression of severe 
preeclampsia (HELLP syndrome).7 Amburgey et 
al reported that in preeclamptic women, maternal 
hemoglobin concentration is significantly elevated 
prior to delivery and found a statistically significant 
inverse correlation to birth weight percentile of the 
newborns.8
 The aim of this study was to compare the 
serum level of Lactate dehydrogenase (LDH), 
Homocystein, Hemoglubin and platelet in pregnant 
women diagnosed as pre-eclampsia and a normal 
group.
METHODOLOGY
 In this case control study, 50 cases of pre-
eclampsia were selected from women hospitalized 
in Dezyani hospital, Gorgan city, Northeastern Iran 
from 2007-2008. For the control group, fifty healthy 
pregnant women were matched about age and 
parity. Pre-eclampsia criteria were as followings: 
1-Blood pressure more than or equal to 140/ 90 mm 
hg and 2- Proteinuria greater or equal to 300 mg/ 24 
hours urine sample in third trimester. 
 Demographic data was gathered in a checklist. 
Verbal informed consent was taken from all partici-
pants. Blood samples were tested for hemoglobin, 
platelet, LDH, hemocystein and cratinine. Creati-
nine was measured with photometry. Measure-
ment of LDH was done with PARS AZMOON kit 
with DJKC method and based on the conversion of 
pyrovate to lactate and photomett clinic II that the 
enzyme was evaluated with kinetic method. Hemo-
cystein was measured by Axis-shield-kit ELISA 
method. Data were analyzed by the mean of SPSS-
14 program and Chi-2 or t-student were used for 
the relation between variables.
RESULTS
 The mean age was 26.8± 4.67 years and 26.4± 
4.62 years in pre-eclampsia group and controls, 
respectively. Number of abortion and history of it 
was not significant between the two groups. In both 
groups 50% were anemic (Hemoglubin<9ng/dl).
 LDH level was not statistically different between 
healthy and pre-eclamptic individuals. Six cases 
(12%) in controls and 9 cases (18%) in pre-eclamptic 
group had thrombocytopenia but it was not 
statistically significant. Hemocystein level was 
more than normal range in five patients with pre-
eclampsia (P-value <0.001). Table-I
Table-I: Mean (± SD) of demographic data and 
measured laboratory tests in pregnant healthy
women compared to preeclamptics.
Variables Pre-eclamptics Healthy
Age (years) 26.8± 4.67 26.4± 4.62
Parity 0.96± 1.21 0.8± 1.1
Gravid 2.1± 1.26 2.06± 1.23
BMI (kg/m2) 30.03± 6.2 27.21± 3.76
Hb (ng/dl) 11.01± 1.49 10.92± 0.9
Plt (/mm3) 203820± 53151.18 196940± 47857.53
LDH (U/L) 230.92± 112.87 187.06± 79.08
Homocystein 11.23± 4.46 5.47± 2.65
  (µmol/L)
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 Differences between the family incomes were 
statistically significant (P-value<0.01), in pre-
eclampsia group most of the patients were median 
income. Table-II
 Mean of BMI was 30.03±6.2 kg/m2 and 27.21±3.76 
kg/m2 in pre-eclampsia and control group, 
respectively. Number of patients in pre-eclampsia 
group was increased with increasing BMI and the 
difference was significant between two groups 
(P-value<0.01). Table-III.
DISCUSSION
 In the present study, hemocystein level was sig-
nificantly higher in pre-eclampsia patients and all 
high hemocystein levels were seen in severe preec-
lampsia but LDH level had no significant difference. 
Mean LDH levels were higher in our preeclamptic 
women, may be because of the cellular damage due 
to preeclampsia that release LDH enzyme.
 Braekke et al in 2007 and Makedos et al in 2007 
had the same results but Fernandes et al in 2005 did 
not find significant relation between hemocystein 
concentration and preeclampsia.10-12 Ingee et al 
in 2005, showed that hemocystein concentration 
in plasma increased in severe preeclampsia and 
eclampsia.9-12
 Our results showed that BMI > 30 could be one 
of the factors that had significant relation with 
increasing risk of preeclampsia. Other studies 
showed that patients with BMI>30 had increased 
risk of pre-eclampsia.13 So, it should be considered 
as a modifiable risk factor in the progression of 
preeclampsia and preventing programs should be 
scheduled for all at risk women.  
 As shown in Table-II, a significant relationship 
was reported between family income and pre-
eclampsia incidence. Some researchers concluded 
that pre-eclampsia incidence is lower in better so-
cioeconomic condition14 but in this study we didn’t 
have such finding. We recorded income by asking 
patients and may be it is not a proper way for evalu-
ating the income. Further studies are needed.
 In our study, half of the women were anemic in 
both groups thus no difference was seen. Phalopra-
karn et al concluded that women with higher hea-
moglubin level had more pre-eclampsia risk15 and 
maternal hemoglobin concentrations are signifi-
cantly elevated prior to delivery in pre-eclampsia8, 
but our reports did not show this result.
 Hence it could be concluded that some modifiable 
risk factors such as BMI and family income 
are among the important factors which could 
significantly affect the pregnancy via occurrence 
of pre-eclampsia and there are serum factors like 
hemocystein which is higher in those suffered 
from pre-eclampsia. So it could be suggested to 
pay more attention to BMI of pregnant women, 
before and during the pregnancy and also evaluate 
hemocystein as a probable marker of pre-eclampsia 
in further large studies.
Limitations: It was not planned to follow up all 
patients and we were not aware of their medications.
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